FDMT250117P17500
- 11.74
- 0.000.00%
4D Molecular Therapeutics Newsroom
BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $46
4D Molecular Therapeutics Analyst Ratings
Morgan Stanley Initiates 4D Molecular Therapeutics(FDMT.US) With Sell Rating, Announces Target Price $8
Chardan Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $39
4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital
RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating
H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36
Barclays Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $45
Barclays Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data
4D Molecular Therapeutics Analyst Ratings
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics(FDMT.US) to Hold Rating
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $82
4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $79
Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Satellos Bioscience (MSCLF)
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40
4D Molecular Therapeutics (FDMT) Receives a Buy From RBC Capital
The Latest Analyst Ratings For 4D Molecular Therapeutics